Mineralys Therapeutics, Inc.

At Mineralys Therapeutics, our purpose is to create more, better days for people dealing with #hypertension and cardio-renal-metabolic disorders. This week, our team came together in Boulder, Colorado, for our annual all-staff meeting. United by this purpose, we delved into the opportunity we have to transform the treatment of hypertension and for a multitude of cardio-renal-metabolic disorders. The summit wasn't just about business. We also dedicated time to giving back to the Boulder community with a volunteer initiative and a refreshing group hike. It was a powerful reminder of the impact our work can have on people. As we move forward, the energy and ideas generated during our time together will propel us through the rest of 2024 and beyond. We are a team united in our commitment to addressing some of the largest unmet medical needs today. Together, we're working tirelessly to create more, better days. #Aldosterone #CardioRenalMetabolic #DrugDiscovery #Leadership #TeamWork #PatientCare

Last week we announced the appointment of Alexander M. Gold, MD, to our Board of Directors. Dr. Gold brings over 20 years of experience leading the development, approval, and commercialization of new therapies. $MLYS

There is a link between uncontrolled #hypertension and certain conditions like obesity, where dysregulated aldosterone may be hindering blood pressure control. In these patients, a better-targeted treatment may be the solution. #HighBloodPressureMonth

We’re honored to have received the Life Sciences & Healthcare Investment Deal award from Philadelphia Alliance for Capital and Technologies (PACT) at the 2024 PACT Enterprise Awards this past Wednesday. With the Philadelphia region being home to some of the top innovators and leaders across the technology, life sciences and healthcare industries, we couldn’t be more proud to be among this year’s winners. Listen to PACT’S interview with our CEO, Jon Congleton, to learn more. $MLYS #HealthcareInnovation #Hypertension

#Hypertension puts people at a high risk of serious health outcomes, yet ~50% of patients have blood pressure that remains uncontrolled. Read about our novel approach, which was developed to address a key factor – aldosterone. #HighBloodPressureMonth

A new study from researchers at Harvard Medical School looked at a decade’s worth of data from over 10K people who participated in the National Health and Nutrition Examination Survey (NHANES) to determine stages of cardiovascular, kidney, and metabolic (CKM) diseases, which is a group of disorders that are interrelated and can lead to #heartdisease if left unchecked. They found that 90% of American adults met the criteria for early, middle or late stages of CKM syndrome. Additionally, 15% were categorized as having advanced disease – and given this number remained consistent, the researchers hypothesized that the #obesity epidemic may be playing a part. #HighBloodPressureMonth

In this article for #HighBloodPressureMonth, our Chief Executive Officer, Jon Congleton, discusses the limitations of current medications for high blood pressure control and the need for more targeted therapies.

Last month we were honored with Life Sciences Pennsylvania's “2023 Deal of the Year” award for our successful IPO in the midst of a difficult year for the #biotech sector. Listen to the podcast episode with Jon Congleton, President and CEO, to learn more: https://lnkd.in/ePBHA4MF #MLYS

Resistant hypertension is defined by high #bloodpressure that persists despite taking ≥3 medications, and among the possible causes is dysregulated aldosterone. Read about this hormone's role, and how we're working to address it. #HighBloodPressureMonth

Today we reported financial results for the quarter ending March 31, 2024. Read our press release for highlights, including anticipated readouts from our pivotal trials for lorundrostat in #hypertension, and proof-of-concept in hypertension and #CKD. #MLYS